187 related articles for article (PubMed ID: 23714726)
1. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.
Tanaka K; Eskin A; Chareyre F; Jessen WJ; Manent J; Niwa-Kawakita M; Chen R; White CH; Vitte J; Jaffer ZM; Nelson SF; Rubenstein AE; Giovannini M
Clin Cancer Res; 2013 Jul; 19(14):3856-70. PubMed ID: 23714726
[TBL] [Abstract][Full Text] [Related]
2. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.
Zhu H; Woolfenden S; Bronson RT; Jaffer ZM; Barluenga S; Winssinger N; Rubenstein AE; Chen R; Charest A
Mol Cancer Ther; 2010 Sep; 9(9):2618-26. PubMed ID: 20643786
[TBL] [Abstract][Full Text] [Related]
3. A novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo.
Cha JR; St Louis KJ; Tradewell ML; Gentil BJ; Minotti S; Jaffer ZM; Chen R; Rubenstein AE; Durham HD
Cell Stress Chaperones; 2014 May; 19(3):421-35. PubMed ID: 24092395
[TBL] [Abstract][Full Text] [Related]
4. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
5. Stereospecific antitumor activity of radicicol oxime derivatives.
Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
[TBL] [Abstract][Full Text] [Related]
6. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
7. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
12. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
13. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
14. Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.
Amici R; Bigogno C; Boggio R; Colombo A; Courtney SM; Dal Zuffo R; Dondio G; Fusar F; Gagliardi S; Minucci S; Molteni M; Montalbetti CA; Mortoni A; Varasi M; Vultaggio S; Mercurio C
ChemMedChem; 2014 Jul; 9(7):1574-85. PubMed ID: 24753447
[TBL] [Abstract][Full Text] [Related]
15. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
16. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.
Ye M; Huang W; Wu WW; Liu Y; Ye SN; Xu JH
Oncotarget; 2017 Feb; 8(9):15364-15376. PubMed ID: 28157708
[TBL] [Abstract][Full Text] [Related]
17. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.
Lin P; Yi Y; Lu M; Wang M; Yang Y; Lu Y; Song S; Zheng Z; Deng X; Zhang L
Anticancer Drugs; 2015 Jan; 26(1):25-34. PubMed ID: 25014191
[TBL] [Abstract][Full Text] [Related]
19. Reduced RAC1 activity inhibits cell proliferation and induces apoptosis in neurofibromatosis type 2(NF2)-associated schwannoma.
Wang Y; Wang B; Li P; Zhang Q; Liu P
Neurol Res; 2017 Dec; 39(12):1086-1093. PubMed ID: 28934903
[TBL] [Abstract][Full Text] [Related]
20. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
